Publication | Open Access
OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results
35
Citations
0
References
2023
Year
Hematological MalignancyMedicineMetronomic TherapyPharmacotherapyOa01.04 Five-year SurvivalExtension Study ResultsOncologyRadiation OncologyEs-sclc Treated
No additional data available for this publication yet. Check back later!